Mpox Clinical Research

Ellsworth, Glesby, Torres, Wilkin

After encountering an initial wave of Mpox (formerly known as Monkeypox) in New York City, our Infectious Diseases investigators quickly rallied to implement an expanded access program for tecovirimat, an antiviral drug .  

In addition, the team developed and disseminated a management algorithm.  Under the leadership of Dr. Tim Wilkin, our AIDS Clinical Trials Group initiated a randomized, placebo-controlled trial of tecovirimat, which is currently being conducted through the Cornell Clinical Trials Unit (CCTU) and internationally through the Study of Tecovirimat for Human Monkeypox Virus (STOMP trial).  

McLean J, Stoeckle K, Huang S, Berardi J, Gray B, Glesby MJ, Zucker J. Tecovirimat Treatment of People With HIV During the 2022 Mpox Outbreak : A Retrospective Cohort Study. Ann Intern Med. 2023 May;176(5):642-648. 

Torres HM, Ellsworth G, Zucker J, Glesby MJ. Approaching monkeypox: a guide for clinicians. Top Antivir Med. 2022 Oct-Nov;30(4):575-581. PMID: 36375131; PMCID: PMC9681140.